Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19

  • Phase III study did not meet its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications (death, mechanical ventilation or ICU care)1
  • Detailed results will be submitted for publication to support scientific understanding of JAK inhibition in COVID-19 and inform ongoing research
  • Novartis commitment to address COVID-19 pandemic remains strong with multiple research collaboration initiatives ongoing

Basel, December 14, 2020 …

/by

Novartis receives EU approval for Leqvio®* (inclisiran), a first-in-class siRNA to lower cholesterol with two doses a year**

  • Leqvio® (inclisiran) is the first and only approved small-interfering RNA (siRNA) low-density lipoprotein cholesterol (LDL-C) lowering treatment in Europe1-3
  • Cardiovascular disease causes 3.9 million deaths annually in Europe, and 80% of high-risk patients do not reach guideline-recommended LDL-C targets despite the widespread use of statins4-7
  • Approval …
/by

Novartis Kisqali® data demonstrate superior benefit across main intrinsic subtypes in metastatic breast cancer

  • Findings presented at SABCS from largest intrinsic subtype analysis show Kisqali is unique among CDK4/6 inhibitors, delivers consistent efficacy across main HR+/HER2- intrinsic subtypes1
  • Benefit seen even in patients with the endocrine-resistant HER2-enriched subtype, who face poor prognosis with …
/by

Novartis Kisqali® demonstrates nearly five years median overall survival in metastatic breast cancer

  •  MONALEESA-7 median overall survival (OS) results reinforce Kisqali as the CDK4/6 inhibitor with unrivaled OS evidence1

  • Kisqali plus endocrine therapy had a median OS of nearly five years (58.7 months), the longest ever reported for premenopausal women with HR+/HER2- metastatic breast cancer (MBC), after a median of 53.5 months follow-up1

  • Kisqali …
/by

Novartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR rate to Bosulif®* in chronic myeloid leukemia trial

  • At 24 weeks, asciminib nearly doubled the major molecular response (MMR) rate compared to Bosulif® (bosutinib)*, in patients resistant to, or intolerant of, at least two prior tyrosine kinase inhibitor (TKI) therapies1

  • Despite advances in chronic myeloid leukemia (CML) care, many patients are at risk of disease …
/by

Novartis analyses confirm benefit of Kymriah® with clinically meaningful rates of complete response seen in patients with certain advanced lymphomas

  • Interim analysis from the investigational ELARA study shows, 65% of patients with r/r follicular lymphoma evaluated for efficacy achieved a complete response and the overall response rate was 83%1
  • Longer-term median follow-up of 40 months from the JULIET study showed a 33% two-year progression-free survival rate in patients with r/r DLBCL2
  • Both ELARA and JULIET trials reaffirm safety profile of Kymriah with no new short- or long-term safety signals identified

Basel, December 5, 2020 …

/by

Novartis announces first data from REACH3 trial showing Jakavi® (ruxolitinib) significantly improved outcomes in patients with steroid-resistant/dependent chronic GvHD

  • Results of REACH3 trial also demonstrate significant improvements in failure-free survival (FFS) and patient-reported symptoms1
  • Chronic graft-versus-host disease (GvHD) is a life-threatening complication of stem cell transplants and half of patients become steroid refractory/dependent2,3
  • Findings from the study were presented …
/by

The Co-Creating Impact Summit for the society and the planet

At Novartis, we know that our impact extends beyond the lives we touch with our medicines, and the performance we deliver for our stakeholders. We aim to have a positive impact on the communities in which we work, and build trust with society.

Our flagship Co-Creating Impact Summit on December 9, 2020, will provide an opportunity to build on the work we have already done in this area, and articulate the social, environmental and economic impact Novartis has on society, and on our planet.

With the rapidly changing ESG landscape, amplified by the COVID-19 pandemic, the upcoming …

/by

Why healthcare’s digital moment is now

In this fireside chat, Bertrand and Peter explore Microsoft’s health moonshots, COVID response and more.

/by

Why healthcare’s digital moment is now

In this fireside chat, Bertrand and Peter explore Microsoft’s health moonshots, COVID response and more.

/by